Stock listing
Frankfurt:ILA Imugene Ltd Aktie
German listing (Frankfurt) of Imugene Ltd · home listing ASX:IMU
Follow Imugene Ltd into a list and get an email when it puts out news.
Share price · FWB:ILA
€0.018 EUR +0.001 (+2.9%)
Close on Nov 20, 2026
Past year -85.0% · daily closes, Nov 20, 2025 – Nov 5, 2026, adjusted for splits- Day range
- €0.018 – €0.018 EURNov 20, 2026
- Market cap
- €9.69M EURAt the close on Nov 20, 2026 · price × 554.0M shares outstanding
- 52-week range
- €0.018 – €0.200 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €80 EURMedian day 0 shares · 45 days with no trades · last 3 months, Aug 20, 2026 – Nov 5, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|
| ASX:IMU · Home | $0.032 AUD | +0.001 (+3.2%) | 802,833 | $0.031 | $0.032 | $0.031 | $0.031 | Close on Nov 20, 2026 |
|---|
| OTC:IUGNF | $0.031 USD | +0.002 (+6.9%) | 12,656 | $0.021 | $0.031 | $0.021 | $0.029 | Close on Nov 20, 2026 |
|---|
| Frankfurt:ILA | €0.018 EUR | +0.001 (+2.9%) | — | €0.018 | €0.018 | €0.018 | €0.017 | Close on Nov 20, 2026 |
|---|
Daily closes
Last 3 months, Aug 20, 2026 – Nov 5, 2026 · FWB:ILA · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|
| €0.023 | +0.001 | +4.5% | €0.023 | €0.023 | €0.023 | 20,000 |
|---|
| €0.022 | +0.003 | +15.8% | €0.022 | €0.022 | €0.022 | 20,000 |
|---|
| €0.019 | -0.001 | -5.0% | €0.019 | €0.019 | €0.019 | 0 |
|---|
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 |
|---|
| €0.020 | -0.001 | -4.8% | €0.020 | €0.020 | €0.020 | 0 |
|---|
| €0.021 | +0.001 | +5.0% | €0.021 | €0.021 | €0.021 | 0 |
|---|
| €0.020 | 0.000 | 0.0% | €0.020 | €0.020 | €0.020 | 0 |
|---|
| €0.020 | -0.004 | -16.7% | €0.020 | €0.020 | €0.020 | 0 |
|---|
| €0.024 | +0.001 | +4.3% | €0.024 | €0.024 | €0.024 | 10,000 |
|---|
| €0.023 | +0.001 | +4.5% | €0.023 | €0.023 | €0.023 | 0 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 117 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.022 | 0.000 | 0.0% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.022 | -0.001 | -4.3% | €0.022 | €0.022 | €0.022 | 0 |
|---|
| €0.023 | 0.000 | 0.0% | €0.023 | €0.023 | €0.023 | 0 |
|---|
| €0.023 | 0.000 | 0.0% | €0.023 | €0.023 | €0.023 | 0 |
|---|
| €0.023 | 0.000 | 0.0% | €0.023 | €0.023 | €0.023 | 0 |
|---|
| €0.023 | -0.004 | -14.8% | €0.023 | €0.023 | €0.023 | 10,000 |
|---|
| €0.027 | -0.001 | -3.6% | €0.027 | €0.027 | €0.027 | 0 |
|---|
| €0.028 | -0.012 | -30.0% | €0.020 | €0.028 | €0.020 | 30,000 |
|---|
| €0.040 | 0.000 | 0.0% | €0.040 | €0.040 | €0.040 | 0 |
|---|
| €0.040 | 0.000 | 0.0% | €0.040 | €0.040 | €0.040 | 0 |
|---|
| €0.040 | +0.014 | +53.8% | €0.030 | €0.040 | €0.030 | 10,000 |
|---|
| €0.026 | -0.001 | -3.7% | €0.026 | €0.026 | €0.026 | 0 |
|---|
| €0.027 | +0.001 | +3.8% | €0.027 | €0.027 | €0.027 | 0 |
|---|
| €0.026 | 0.000 | 0.0% | €0.026 | €0.026 | €0.026 | 0 |
|---|
| €0.026 | 0.000 | 0.0% | €0.026 | €0.026 | €0.026 | 0 |
|---|
| €0.026 | 0.000 | 0.0% | €0.026 | €0.026 | €0.026 | 0 |
|---|
| €0.026 | -0.001 | -3.7% | €0.026 | €0.026 | €0.026 | 0 |
|---|
| €0.027 | -0.003 | -10.0% | €0.026 | €0.027 | €0.026 | 0 |
|---|
| €0.030 | 0.000 | 0.0% | €0.030 | €0.030 | €0.030 | 0 |
|---|
| €0.030 | 0.000 | 0.0% | €0.030 | €0.030 | €0.030 | 0 |
|---|
| €0.030 | +0.001 | +3.4% | €0.030 | €0.030 | €0.030 | 0 |
|---|
| €0.029 | -0.008 | -21.6% | €0.029 | €0.029 | €0.029 | 26,552 |
|---|
| €0.037 | -0.007 | -15.9% | €0.037 | €0.037 | €0.037 | 13,276 |
|---|
| €0.044 | +0.008 | +22.2% | €0.040 | €0.044 | €0.040 | 10,000 |
|---|
| €0.036 | 0.000 | 0.0% | €0.036 | €0.036 | €0.036 | 0 |
|---|
| €0.036 | 0.000 | 0.0% | €0.036 | €0.036 | €0.036 | 0 |
|---|
| €0.036 | -0.001 | -2.7% | €0.036 | €0.036 | €0.036 | 0 |
|---|
| €0.037 | +0.001 | +2.8% | €0.037 | €0.037 | €0.037 | 0 |
|---|
| €0.036 | -0.014 | -28.0% | €0.036 | €0.036 | €0.036 | 0 |
|---|
| €0.050 | 0.000 | 0.0% | €0.050 | €0.050 | €0.050 | 0 |
|---|
| €0.050 | +0.005 | +11.1% | €0.050 | €0.050 | €0.050 | 3,000 |
|---|
| €0.045 | 0.000 | 0.0% | €0.045 | €0.045 | €0.045 | 0 |
|---|
| €0.045 | 0.000 | 0.0% | €0.045 | €0.045 | €0.045 | 0 |
|---|
| €0.045 | 0.000 | 0.0% | €0.045 | €0.045 | €0.045 | 0 |
|---|
| €0.045 | 0.000 | 0.0% | €0.045 | €0.045 | €0.045 | 0 |
|---|
| €0.045 | 0.000 | 0.0% | €0.045 | €0.045 | €0.045 | 0 |
|---|
| €0.045 | -0.001 | -2.2% | €0.045 | €0.045 | €0.045 | 0 |
|---|
| €0.046 | +0.001 | +2.2% | €0.046 | €0.046 | €0.046 | 0 |
|---|
| €0.045 | 0.000 | 0.0% | €0.045 | €0.045 | €0.045 | 0 |
|---|
Splits
1 split · FWB:ILA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|
| 1-for-34 | Consolidation |
|---|
- Ticker
- Frankfurt:ILA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Latest deck · Jul 7, 2026
Investor deck · 29 slides
Imugene Ltd on 6ix
- News releases
- 57 in the last 12 months · 266 in all · newest Nov 20, 2026 · oldest 2016
- Decks
- 54 decks · latest Jul 7, 2026
Where Imugene Ltd is listed
| Listing | Exchange | Country | Currency |
|---|
| ASX:IMU · Home listing | ASX | Australia | AUD |
|---|
| Stuttgart:ILA | Stuttgart | Germany | EUR |
|---|
| OTC:IUGNF | OTC | United States | USD |
|---|
| Frankfurt:ILA · This page | Frankfurt | Germany | EUR |
|---|
Valuation
Price/book 2.0× against a median of 4.5×: 4th lowest of 8 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $21.40M AUD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.7×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.23 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.055 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|
| Paul Hopper | Executive Chairman |
|---|
Board
| Director | Role |
|---|
| Paul Hopper | Executive Chairman |
|---|
| Charmaine Gittleson | Non-Executive Director |
|---|
| Jakob Dupont | Non-Executive Director |
|---|
| Kim Drapkin | Non-Executive Director |
|---|
| Michael Kotsanis | Non-Executive Director |
|---|
Events
| Quarter | Results | Share move |
|---|
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −1.5% |
|---|
| Q4 2025 | Aug 25, 2025 | −8.8% |
|---|
| Quarter to Mar 31, 2025 | May 28, 2025 | −5.9% |
|---|
| Q2 2025 | Feb 27, 2025 | +2.8% |
|---|
| Quarter to Sep 30, 2024 | Nov 27, 2024 | +2.6% |
|---|
| Q4 2024 | Aug 30, 2024 | +15.3% |
|---|
| Quarter to Mar 31, 2024 | May 29, 2024 | −2.9% |
|---|
| Q2 2024 | Feb 28, 2024 | +4.3% |
|---|
| Quarter to Sep 30, 2023 | Oct 31, 2023 · Before open | +2.4% |
|---|
| Q4 2023 | Aug 25, 2023 · Before open | −2.8% |
|---|
All 18 quarters
| Quarter | Results | Share move |
|---|
| Q3 2023 | Apr 28, 2023 · After close | +4.0% |
|---|
| Q2 2023 | Feb 28, 2023 · After close | 0.0% |
|---|
| Q1 2023 | Nov 30, 2022 | +5.6% |
|---|
| Q4 2022 | Aug 31, 2022 · Before open | +8.3% |
|---|
| Q3 2022 | Jun 1, 2022 | −12.8% |
|---|
| Q2 2022 | Feb 27, 2022 | 0.0% |
|---|
| Q4 2021 | Aug 30, 2021 | +20.3% |
|---|
| Q2 2021 | Feb 26, 2021 | −4.8% |
|---|
Open Events
Decks
Show 50 decks
| Deck | Kind | Slides | Date |
|---|
| Investor Presentation (July 2024) | Investor deck | 33 slides | July 2024 |
|---|
| Bell Potter Emerging Leaders Conference 2024 | Conference | 28 slides | May 2024 |
|---|
| Investor Presentation (May 2024) | Investor deck | 30 slides | May 2024 |
|---|
| JP Morgan Healthcare Conference 2024 | Conference | 35 slides | Jan 10, 2024 |
|---|
| Shareholder Meeting (November 2023) | Shareholder meeting | 14 slides | Nov 30, 2023 |
|---|
| Shareholder Meeting (September 2023) | Shareholder meeting | 17 slides | Sep 28, 2023 |
|---|
| Investor Presentation (August 2023) | Investor deck | 30 slides | Aug 18, 2023 |
|---|
| Investor Presentation (July 2023) | Investor deck | 38 slides | Jul 20, 2023 |
|---|
| NWR Healthcare Conference 2023 | Conference | 34 slides | Mar 22, 2023 |
|---|
| Non-Deal Roadshow (March 2023) | Roadshow | 32 slides | Mar 15, 2023 |
|---|
| JP Morgan Healthcare Conference 2023 | Conference | 38 slides | Jan 9, 2023 |
|---|
| Shareholder Meeting (November 2022) | Shareholder meeting | 15 slides | Nov 17, 2022 |
|---|
| Investor Presentation (November 2022) | Investor deck | 31 slides | Nov 15, 2022 |
|---|
| Shareholder Meeting (November 2021) | Shareholder meeting | 11 slides | Nov 19, 2021 |
|---|
| Investor Presentation (November 2021) | Investor deck | 18 slides | Nov 1, 2021 |
|---|
| Investor Presentation (October 2021) | Investor deck | 31 slides | Oct 5, 2021 |
|---|
| Investor Presentation (August 2021) | Investor deck | 18 slides | Aug 5, 2021 |
|---|
| Investor Presentation (July 2021) | Investor deck | 28 slides | Jul 29, 2021 |
|---|
| Investor Presentation (June 2021) | Investor deck | 25 slides | Jun 11, 2021 |
|---|
| Investor Presentation (May 2021) | Investor deck | 18 slides | May 18, 2021 |
|---|
| Shareholder Meeting (November 2020) | Shareholder meeting | 14 slides | Nov 24, 2020 |
|---|
| Investor Presentation (November 2020) | Investor deck | 31 slides | Nov 24, 2020 |
|---|
| Investor Presentation (November 2019) | Investor deck | 31 slides | Dec 2, 2019 |
|---|
| Shareholder Meeting (November 2019) | Shareholder meeting | 10 slides | Nov 8, 2019 |
|---|
| Investor Presentation (November 2019) | Investor deck | 40 slides | Nov 6, 2019 |
|---|
| 15th Bioshares Biotech Summit 2019 | Conference | 25 slides | Jul 26, 2019 |
|---|
| Investor Presentation (July 2019) | Investor deck | 35 slides | Jul 15, 2019 |
|---|
| Planet MicroCap Showcase 2019 | Conference | 34 slides | May 1, 2019 |
|---|
| Investor Presentation (April 2019) | Investor deck | 27 slides | Apr 16, 2019 |
|---|
| Investor Presentation (March 2019) | Investor deck | 25 slides | Mar 26, 2019 |
|---|
| Investor Presentation (January 2019) | Investor deck | 20 slides | Jan 10, 2019 |
|---|
| Shareholder Meeting (November 2018) | Shareholder meeting | 12 slides | Nov 13, 2018 |
|---|
| Bioshares Biotech Summit 2018 | Conference | 16 slides | Jul 27, 2018 |
|---|
| Shareholder Meeting (July 2018) | Shareholder meeting | 10 slides | Jul 9, 2018 |
|---|
| Investor Presentation (June 2018) | Investor deck | 24 slides | Jun 7, 2018 |
|---|
| Investor Presentation (June 2018) | Investor deck | 23 slides | June 2018 |
|---|
| Investor Presentation (January 2018) | Investor deck | 34 slides | Jan 9, 2018 |
|---|
| Investor Presentation (November 2017) | Investor deck | 32 slides | November 2017 |
|---|
| Investor Presentation (October 2017) | Investor deck | 36 slides | October 2017 |
|---|
| Investor Presentation (July 2017) | Investor deck | 40 slides | July 2017 |
|---|
This page holds 50 of 54 decks. Open Decks
Open Decks
Financings
| Raise | Date | In US dollars |
|---|
| Convertible notes (New Notes) Terms changed: convertible Buyers: CVI Investments, Inc. | Nov 2, 2026 | |
|---|
| Convertible notes (TAR Notes) Terms changed: convertible Buyers: CVI Investments, Inc. | Nov 2, 2026 | |
|---|
| Private placement of fully paid ordinary shares Closed: A$0.095 a share | Sep 1, 2026 | |
|---|
| Convertible notes (TAR Notes) and warrants Closed: A$2.1M raised · Warrants at A$0.0664 for 60 months Buyers: CVI Investments, Inc. ($2,100,000 worth of TAR Notes and 25,301,205 New Warrants) Use of proceeds: Fund Cohort 2 and new Cohort 3 (BTKi) of its Phase 1b trial, plus general administrative and working capital | Aug 27, 2026 | US$1.49M |
|---|
| Private placement of new shares with attaching options Announced: A$22.5M · A$0.33 a share · Warrants at A$0.43 Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26 | Jul 16, 2025 | US$14.67M |
|---|
| Share purchase plan of new shares with attaching options Announced: A$15M · A$0.33 a share · Warrants at A$0.43 Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26 | Jul 16, 2025 | US$9.78M |
|---|
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|
| Revenue | | 4.40M | 4.97M | 11.8M | 13.0M | 7.23M | 4.13M | 4.13M | 1.84M | 1.16M |
|---|
| Cost of revenue | 6.84M | 3.38M | 5.84M | 2.20M | 2.41M | 1.96M | 82.5K | 63.3K | 2.68K | 1.74K |
|---|
| Gross profit | -6.84M | 4.40M | 4.97M | 9.57M | 10.6M | 5.27M | 4.05M | 4.06M | 1.84M | 1.16M |
|---|
| Research and development | 50.9M | 46.7M | 86.9M | 30.9M | 36.6M | 15.4M | 9.36M | 7.61M | 4.15M | 2.47M |
|---|
| Selling, general and administrative | 32.2M | 27.8M | 59.9M | 17.8M | 12.1M | 9.44M | 5.52M | 4.78M | 1.21M | 894.1K |
|---|
| Operating income | -75.0M | -70.9M | -140.9M | -51.3M | -50.7M | -25.7M | -10.8M | -12.4M | -5.78M | -3.69M |
|---|
| Depreciation and amortization | 6.84M | 3.38M | 5.84M | 2.20M | 2.41M | 1.96M | 82.5K | 63.3K | 2.68K | 1.74K |
|---|
| EBITDA | -68.1M | -67.6M | -135.1M | -49.1M | -48.3M | -23.7M | -10.7M | -12.3M | -5.78M | -3.68M |
|---|
| Interest expense | 125.5K | 162.5K | 478.4K | 27.5K | 13.6K | 5.02K | 5.03K | 6.11K | 0 | 0 |
|---|
| Income before tax | -107.3M | -69.0M | -154.3M | -49.7M | -50.5M | -25.7M | -14.6M | -7.78M | -5.77M | -3.67M |
|---|
| Income tax | -2.00M | -4.04M | -4.62M | -11.7M | -12.6M | -7.23M | -4.13M | -4.13M | -1.84M | -1.16M |
|---|
| Net income | -105.3M | -69.0M | -149.7M | -37.9M | -37.9M | -18.5M | -10.5M | -7.78M | -3.93M | -2.51M |
|---|
| Earnings per share, basic | -0.32 | -0.32 | -0.72 | -0.01 | -0.23 | -0.13 | -0.09 | -0.00 | -0.05 | -0.04 |
|---|
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|
| Cash and equivalents | 2.63M | 21.9M | 93.1M | 153.2M | 99.9M | 29.5M | 30.1M | 19.0M | 7.82M | 4.81M |
|---|
| Short-term investments | | 2.08M | 1.44M | | -1 | | | | | 0 |
|---|
| Receivables | 2.38M | 10.0M | 12.6M | 12.1M | 12.8M | 6.66M | 4.19M | 4.22M | 1.91M | 1.22M |
|---|
| Inventory | 4.41M | | -2.23M | | | | | -4.22M | -1.91M | -1.22M |
|---|
| Current assets | 9.82M | 41.7M | 113.0M | 165.7M | 113.8M | 36.3M | 34.5M | 23.4M | 9.83M | 6.05M |
|---|
| Property, plant and equipment | | 1.73M | 1.70M | 683.0K | 862.8K | 466.0K | 155.6K | 233.1K | 3.90K | 3.25K |
|---|
| Total assets | 23.0M | 83.6M | 151.4M | 197.1M | 147.6M | 71.8M | 65.2M | 30.8M | 16.9M | 12.7M |
|---|
| Accounts payable | 5.57M | 6.84M | 5.97M | 2.34M | 4.51M | 759.7K | 1.01M | 1.48M | 288.5K | 16.2K |
|---|
| Current liabilities | 14.0M | 22.2M | 29.3M | 6.08M | 7.42M | 4.46M | 2.90M | 2.42M | 438.2K | 297.5K |
|---|
| Long-term debt | | 2.58M | | | | | | 985.5K | 985.5K | 985.5K |
|---|
| Total debt | 6.30M | 10.7M | 2.19M | 553.5K | 673.4K | 271.0K | 69.3K | 1.11M | | |
|---|
| Total liabilities | 14.0M | 38.6M | 33.1M | 7.44M | 8.90M | 6.79M | 5.40M | 3.48M | 1.44M | 1.28M |
|---|
| Shareholders' equity | 9.01M | 45.0M | 118.3M | 189.6M | 138.7M | 65.0M | 59.8M | 27.3M | 15.5M | 11.4M |
|---|
| Shares outstanding | 326.1M | 218.7M | 208.5M | 6.28B | 165.8M | 137.2M | 119.8M | 3.58B | 77.6M | 61.4M |
|---|
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|
| Cash from operations | -44.9M | -75.6M | -101.7M | -29.8M | -30.7M | -13.1M | -10.1M | -7.91M | -4.51M | -2.67M |
|---|
| Capital spending | -5 | -14.5M | -7.07M | 0 | -257.7K | -5.45M | -1.49M | -128.4K | -3.33K | -2.03K |
|---|
| Free cash flow | -44.9M | -90.0M | -108.8M | -29.8M | -30.9M | -18.6M | -11.6M | -8.04M | -4.51M | -2.68M |
|---|
| Cash from investing | -4.35M | -12.7M | -7.25M | 9.63K | -414.2K | -5.48M | -1.52M | 247.4K | -412.9K | -2.34K |
|---|
| Cash from financing | 30.0M | 17.4M | 49.4M | 83.0M | 101.4M | 18.0M | 22.7M | 18.8M | 7.93M | 5.93M |
|---|
| Dividends paid | | | | -77.9M | -6.01M | -17.9M | -20.9M | | | 0 |
|---|
| Share buybacks | -2.67M | -1.32M | -2.74M | -5.04M | -6.15M | -125.6K | -1.80M | -1.44M | -848.1K | -320.7K |
|---|
| Change in cash | -19.3M | -71.2M | -60.0M | 53.3M | 70.4M | -619.7K | 11.1M | 11.2M | 3.01M | 3.23M |
|---|
Open Financials
Filings
| Filing | Date | Type | Filed with |
|---|
| Change of Director's Interest Notice x2 - KD & JD | Nov 20, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - IMU | Nov 19, 2026 | Financing | ASX |
|---|
| Final Director's Interest Notice - LR | Nov 18, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - IMU | Nov 18, 2026 | Notification letter | ASX |
|---|
| Imugene Receives $2.1M R&D Tax Refund | Nov 15, 2026 | Financing | ASX |
|---|
| Director Resignation and Committee Changes | Nov 10, 2026 | Management or board change | ASX |
|---|
| Results of 2026 Annual General Meeting | Nov 10, 2026 | Meeting outcome | ASX |
|---|
| AGM Presentation | Nov 10, 2026 | Other filings | ASX |
|---|
| Imugene selected for Poster Presentation at 2026 ASH Meeting | Nov 4, 2026 | Operations update | ASX |
|---|
| Positive amendments to Convertible Notes | Nov 2, 2026 | Financing | ASX |
|---|
Show 200 filings
| Filing | Date | Type | Filed with |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Further Responses in azer-cel Phase 1b Trial | Oct 18, 2026 | Operations update | ASX |
|---|
| Notification of cessation of securities - IMU | Oct 16, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Oct 14, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Oct 13, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 8, 2026 | Meeting notice | ASX |
|---|
| Dr John Le Gall appointed Chief Medical Officer | Oct 6, 2026 | Management or board change | ASX |
|---|
| azer-cel BTKi Cohort Reports new Complete & Partial Response | Oct 4, 2026 | Operations update | ASX |
|---|
| Change of Director's Interest Notice - JD | Oct 1, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - IMU | Sep 8, 2026 | Financing | ASX |
|---|
| Cleansing Notice | Sep 1, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Sep 1, 2026 | Financing | ASX |
|---|
| Change of Director's Interest Notice x4 | Sep 1, 2026 | Ownership change notice | ASX |
|---|
| Corporate Governance Statement and Appendix 4G | Aug 28, 2026 | Other filings | ASX |
|---|
| Appendix 4E and Annual Report | Aug 28, 2026 | Annual report | ASX |
|---|
| Notice under section 708A(12C)(e) of the Corporations Act | Aug 27, 2026 | Notification letter | ASX |
|---|
| Notice of Initial Substantial Holding for IMU | Aug 27, 2026 | Ownership change notice | ASX |
|---|
| Becoming a substantial holder for IMU | Aug 26, 2026 | Ownership change notice | ASX |
|---|
| Notification regarding unquoted securities - IMU | Aug 26, 2026 | Other filings | ASX |
|---|
| Notification of cessation of securities - IMU | Aug 26, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Aug 25, 2026 | Financing | ASX |
|---|
| Amendment of Convertible Notes | Aug 20, 2026 | Financing | ASX |
|---|
| Results of Extraordinary General Meeting | Aug 18, 2026 | Meeting outcome | ASX |
|---|
| Letter To Shareholders | Aug 9, 2026 | Other filings | ASX |
|---|
| Expiry Of Listed Options | Aug 5, 2026 | Other filings | ASX |
|---|
| Final Director's Interest Notice - LC | Jul 31, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - IMU | Jul 31, 2026 | Notification letter | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jul 30, 2026 | Quarterly report | ASX |
|---|
| Third response in concurrent BTKi Cohort of azer-cel Trial | Jul 26, 2026 | Operations update | ASX |
|---|
| $11.1 Million Placement Completed to Advance azer-cel | Jul 6, 2026 | Financing | ASX |
|---|
| New Complete Response in the Concurrent BTKi azer-cel Cohort | Jun 30, 2026 | Other filings | ASX |
|---|
| First Complete Response in Concurrent BTKi azer-cel Cohort | Jun 29, 2026 | Other filings | ASX |
|---|
| Azer-cel Granted FDA Fast Track Designation for CLL and MZL | Jun 8, 2026 | Operations update | ASX |
|---|
| First Patient in BTKi Combination Cohort of azer-cel study | May 27, 2026 | Other filings | ASX |
|---|
| Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract | May 21, 2026 | Operations update | ASX |
|---|
| Prospectus | Mar 17, 2026 | Offer document | ASX |
|---|
| $20M placement and SPP, convertible notes amended | Mar 11, 2026 | Financing | ASX |
|---|
| 100% and 80% ORRs in Subset Indications in azer-cel study | Mar 9, 2026 | Operations update | ASX |
|---|
| Trading Halt | Mar 9, 2026 | Trading halt or suspension | ASX |
|---|
| Half Yearly Report and Accounts | Feb 25, 2026 | Interim report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 29, 2026 | Quarterly report | ASX |
|---|
| FDA Supports Strategy Toward Registration for Azer-cel | Dec 7, 2025 | Guidance | ASX |
|---|
| Strategic Collaboration with JW Therapeutics | Nov 26, 2025 | Operations update | ASX |
|---|
| S&P DJI Announces September 2025 Quarterly Rebalance | Sep 5, 2025 | Other filings | ASX |
|---|
| Final Share Purchase Plan Allotment | Aug 28, 2025 | Financing | ASX |
|---|
| Appendix 4E and Annual Report | Aug 25, 2025 | Annual report | ASX |
|---|
| Imugene Capital Raising Presentation | Jul 16, 2025 | Financing | ASX |
|---|
| Imugene Completes $22.5M Placement and c.$15M SPP | Jul 16, 2025 | Financing | ASX |
|---|
| Two Additional Complete Responses in azer-cel Ph1b trial | Jul 13, 2025 | Operations update | ASX |
|---|
| Notice of Extraordinary General Meeting/Proxy Form | May 27, 2025 | Meeting notice | ASX |
|---|
| Azer-cel Granted FDA Fast Track Designation in Blood Cancer | Mar 18, 2025 | Operations update | ASX |
|---|
| S&P DJI Announces March 2025 Quarterly Rebalance | Mar 7, 2025 | Other filings | ASX |
|---|
| Imugene Granted India Patent for Oncolytic Virotherapy CF33 | Feb 26, 2025 | Other filings | ASX |
|---|
| Imugene OnCARlytics Patent Allowance in China | Feb 25, 2025 | Other filings | ASX |
|---|
| Azer-cel demonstrates two additional Complete Responses | Feb 13, 2025 | Operations update | ASX |
|---|
| Imugene Receives A$20 million for Convertible Notes Issuance | Jan 28, 2025 | Financing | ASX |
|---|
| Imugene Receives $11.7m R&D Tax Refund | Jan 10, 2025 | Financing | ASX |
|---|
| First Australian Patient Dosed in Phase 1b azer-cel Trial | Jan 2, 2025 | Operations update | ASX |
|---|
| Issuance of Convertible Notes & Warrants for up to $46m | Dec 23, 2024 | Financing | ASX |
|---|
| Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund | Dec 18, 2024 | Other filings | ASX |
|---|
| onCARlytics Trial Doses First Patient in IT Combination Arm | Nov 10, 2024 | Other filings | ASX |
|---|
| Imugene Opens First Australian Site for azer-cel Trial | Nov 7, 2024 | Other filings | ASX |
|---|
| Complete Response in MAST Study Maintained Over Two Years | Nov 4, 2024 | Other filings | ASX |
|---|
| Imugene Receives Orphan Drug Designation for VAXINIA | Sep 18, 2024 | Operations update | ASX |
|---|
| Three Complete Responses in Azer-Cel Phase 1b Trial | Sep 1, 2024 | Operations update | ASX |
|---|
| First patient dosed in Phase 1 bile tract cancer trial | Jul 9, 2024 | Operations update | ASX |
|---|
| Imugene onCARlytics Doses First Patient in IV Combination | Jun 23, 2024 | Other filings | ASX |
|---|
| Imugene and Kincell Bio Announce Strategic Partnership | Apr 15, 2024 | Acquisition or disposal | ASX |
|---|
| Bile Tract Cancer Study Opens after MAST High Dose Clearance | Apr 14, 2024 | Operations update | ASX |
|---|
| VAXINIA and HER-Vaxx featured at the AACR Annual Meeting | Apr 7, 2024 | Operations update | ASX |
|---|
| Oncolytic Virotherapy CF33 Patent Granted in China | Apr 3, 2024 | Other filings | ASX |
|---|
| Imugene to present at 2024 Cholangiocarcinoma Conference | Apr 2, 2024 | Other filings | ASX |
|---|
| Phase 1 onCARlytics Trial Advances to Combination Arm | Mar 10, 2024 | Operations update | ASX |
|---|
| Phase 1 onCARlytics Trial Doses First Intravenous Patient | Feb 14, 2024 | Other filings | ASX |
|---|
| VAXINIA Phase 1 trial doses patients in higher dose cohorts | Jan 18, 2024 | Other filings | ASX |
|---|
| Phase 1 CF33-hNIS Study Update - Positive Early Signals | Jan 16, 2024 | Other filings | ASX |
|---|
| Imugene and NeoImmuneTech to Improve Cancer Treatments | Dec 11, 2023 | Other filings | ASX |
|---|
| New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS | Dec 5, 2023 | Other filings | ASX |
|---|
| Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine | Dec 5, 2023 | Operations update | ASX |
|---|
| FDA Fast Track Designation Granted for VAXINIA Trial Program | Nov 27, 2023 | Operations update | ASX |
|---|
| Azer-cel Hits Major Milestone in Phase 1b CAR T Trial | Nov 9, 2023 | Other filings | ASX |
|---|
| Phase 1 CF33 VAXINIA Study Update - Positive Early Signals | Nov 5, 2023 | Other filings | ASX |
|---|
| Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study | Nov 1, 2023 | Operations update | ASX |
|---|
| Imugene Phase 1 onCARlytics CD19 virus clinical trial opens | Oct 25, 2023 | Other filings | ASX |
|---|
| Imugene B Cell & OV Platforms Featured at ESMO Congress | Oct 23, 2023 | Operations update | ASX |
|---|
| Azer-cel FDA IND Transferred to Imugene | Sep 27, 2023 | Other filings | ASX |
|---|
| Imugene Closes SPP Raising $18.2 million | Sep 24, 2023 | Financing | ASX |
|---|
| Imugene PD1-Vaxx Update | Sep 11, 2023 | Other filings | ASX |
|---|
| Imugene Receives Positive Feedback From FDA | Sep 10, 2023 | Other filings | ASX |
|---|
| VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1 | Sep 3, 2023 | Other filings | ASX |
|---|
| S&P DJI Announces September 2023 Quarterly Rebalance | Sep 1, 2023 | Other filings | ASX |
|---|
| Preliminary Final Report | Aug 25, 2023 | Results | ASX |
|---|
| Imugene completes $35M Placement & Launches c.$30M SPP | Aug 17, 2023 | Financing | ASX |
|---|
| Imugene Licenses Allogeneic CD19 CAR T Cell Therapy | Aug 15, 2023 | Other filings | ASX |
|---|
| Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy | Aug 13, 2023 | Other filings | ASX |
|---|
| Imugene CF33 Oncolytic Virus Study to be Showcased at SITC | Aug 2, 2023 | Other filings | ASX |
|---|
| Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO | Jul 24, 2023 | Other filings | ASX |
|---|
| Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration | Jul 20, 2023 | Other filings | ASX |
|---|
| Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US | Jul 19, 2023 | Other filings | ASX |
|---|
| New Dose Escalation in Phase I Clinical Trial of CHECKvacc | Jul 6, 2023 | Other filings | ASX |
|---|
| HER-Vaxx induced antibodies correlated with tumour reduction | Jun 29, 2023 | Other filings | ASX |
|---|
| Imugene PD1-Vaxx patent extended to 2040 | Jun 28, 2023 | Other filings | ASX |
|---|
| Imugene Advances VAXINIA MAST Trial to Next IV Cohorts | Jun 8, 2023 | Other filings | ASX |
|---|
| Imugene doses first combination patient in PD1-Vaxx trial | May 31, 2023 | Other filings | ASX |
|---|
| FDA clears Imugene IND for onCARlytics first-in-class study | May 18, 2023 | Other filings | ASX |
|---|
| onCARlytics with ARTEMIS T cells show anti-tumour activity | May 17, 2023 | Other filings | ASX |
|---|
| onCARlytics with Artemis T cells abstract presented at ASGCT | May 2, 2023 | Other filings | ASX |
|---|
| Imugene receives $12.6m R&D tax refund | Apr 25, 2023 | Other filings | ASX |
|---|
| Imugene Images and Follows CHECKVacc in TNBC Patients | Apr 19, 2023 | Other filings | ASX |
|---|
| First patients dosed in IT & IV cohort 3 of VAXINIA trial | Apr 4, 2023 | Other filings | ASX |
|---|
| First Patients Dosed in Combination Study of VAXINIA | Mar 2, 2023 | Other filings | ASX |
|---|
| Imugene PD1-Vaxx Immunotherapy Patent Granted in the US | Feb 9, 2023 | Other filings | ASX |
|---|
| Imugene VAXINIA trial advances to Combination Cohort | Feb 1, 2023 | Other filings | ASX |
|---|
| Imugene Receives Vaxinia Ethics Approval in Australia | Jan 8, 2023 | Other filings | ASX |
|---|
| CHECKVacc Data Presented at the 2022 SABC Symposium | Dec 8, 2022 | Other filings | ASX |
|---|
| First Patient Dosed in VAXINIA Intravenous Cohort 2 | Dec 4, 2022 | Other filings | ASX |
|---|
| Imugene onCARlytics with Estrella ARTEMIS T Cells SITC | Nov 13, 2022 | Other filings | ASX |
|---|
| Dose escalates In Phase I Clinical Trial of New Oncolytic Vi | Nov 11, 2022 | Other filings | ASX |
|---|
| Imugene onCARlytics with blinatumomab SITC presentation | Nov 10, 2022 | Other filings | ASX |
|---|
| Europe Patent granted for iNKT Cell Therapy Platform | Nov 6, 2022 | Other filings | ASX |
|---|
| First patient dosed in VAXINIA intratumoral cohort 2 | Oct 30, 2022 | Other filings | ASX |
|---|
| Preclinical trial of ALA iNKT therapy and IMU onCARlytics | Sep 26, 2022 | Other filings | ASX |
|---|
| First patient IV dosed in VAXINIA Phase 1 clinical trial | Sep 20, 2022 | Other filings | ASX |
|---|
| OGTR grants VAXINIA DIR licence allowing trial expansion | Sep 19, 2022 | Other filings | ASX |
|---|
| Prospectus for the issue of institutional placement options | Sep 16, 2022 | Financing | ASX |
|---|
| IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT | Sep 12, 2022 | Financing | ASX |
|---|
| Imugene doses first patient in nextHERIZON Phase 2 trial | Sep 7, 2022 | Other filings | ASX |
|---|
| Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA | Aug 31, 2022 | Other filings | ASX |
|---|
| Annual Report and Appendix 4E | Aug 30, 2022 | Annual report | ASX |
|---|
| FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACC | Aug 9, 2022 | Other filings | ASX |
|---|
| Imugene Presents New PD1-Vaxx Data at the 2022 WCLC | Aug 7, 2022 | Other filings | ASX |
|---|
| Final HER-Vaxx Phase 2 Trial Overall Survival Results | Jun 26, 2022 | Other filings | ASX |
|---|
| IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL | May 17, 2022 | Other filings | ASX |
|---|
| IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON | May 9, 2022 | Other filings | ASX |
|---|
| Clarification Announcement | May 3, 2022 | Other filings | ASX |
|---|
| Termination of Supply Agreement | May 2, 2022 | Other filings | ASX |
|---|
| Dose Escalation in Phase 1 Clinical Trial of CHECKvacc | Mar 23, 2022 | Other filings | ASX |
|---|
| Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia | Mar 22, 2022 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Clinical Trial Collaboration with Merck | Mar 14, 2022 | Other filings | ASX |
|---|
| Oncolytic Virotherapy CF33 Patent Granted in Japan | Jan 30, 2022 | Other filings | ASX |
|---|
| PD1-Vaxx Clinical Trial Supply Agreement with Roche | Jan 28, 2022 | Other filings | ASX |
|---|
| HER-Vaxx Immunotherapy Patent Granted in Europe | Jan 27, 2022 | Other filings | ASX |
|---|
| Imugene Receives $6.54 million R&D Tax Incentive | Jan 6, 2022 | Other filings | ASX |
|---|
| South Korea HERVaxx Patent Grant | Jan 5, 2022 | Other filings | ASX |
|---|
| Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx | Jan 3, 2022 | Other filings | ASX |
|---|
| FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX | Dec 12, 2021 | Other filings | ASX |
|---|
| Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc | Dec 6, 2021 | Other filings | ASX |
|---|
| S&P DJI Announces December 2021 Quarterly Rebalance | Dec 3, 2021 | Other filings | ASX |
|---|
| Clinical Trial Supply Agreement with Merck KGaA and Pfizer | Nov 15, 2021 | Other filings | ASX |
|---|
| Investor Presentation Imugene Eureka Therapeutics | Oct 31, 2021 | Other filings | ASX |
|---|
| FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF CHECKVACC | Oct 20, 2021 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Immunotherapy Patent Granted in Japan | Sep 21, 2021 | Other filings | ASX |
|---|
| S&P DJI Announces September 2021 Quarterly Rebalance | Sep 3, 2021 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials | Aug 31, 2021 | Other filings | ASX |
|---|
| Appendix 4E and Full Year Statutory Accounts | Aug 30, 2021 | Annual report | ASX |
|---|
| Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx | Aug 26, 2021 | Other filings | ASX |
|---|
| Response to ASX Query | Aug 23, 2021 | Explanation request | ASX |
|---|
| Research partnership with Celularity for solid tumors | Aug 4, 2021 | Other filings | ASX |
|---|
| Prospectus for SPP and Placement Options Offer | Jul 29, 2021 | Financing | ASX |
|---|
| Imugene completes $90 M placement and launches $5 M SPP | Jul 28, 2021 | Financing | ASX |
|---|
| Appendix 4C - Quarterly Report | Jul 23, 2021 | Quarterly report | ASX |
|---|
| FDA IND APPROVAL OF NEW ONCOLYTIC VIROTHERAPY CHECKVACC | Jul 1, 2021 | Other filings | ASX |
|---|
| Investor Presentation | May 17, 2021 | Other filings | ASX |
|---|
| Prestigious Research Journal Publish HER-Vaxx Phase 1B Data | Apr 29, 2021 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Apr 23, 2021 | Quarterly report | ASX |
|---|
| Imugene announces clinical milestone for HER-Vaxx | Apr 20, 2021 | Other filings | ASX |
|---|
| Imugene Oncolytic Virus Presentation at AACR 2021 Meeting | Apr 11, 2021 | Other filings | ASX |
|---|
| Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX | Apr 6, 2021 | Other filings | ASX |
|---|
| S&P DJI Announces March 2021 Quarterly Rebalance | Mar 12, 2021 | Other filings | ASX |
|---|
| Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting | Mar 10, 2021 | Other filings | ASX |
|---|
| Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial | Feb 11, 2021 | Other filings | ASX |
|---|
| Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial | Jan 20, 2021 | Other filings | ASX |
|---|
| IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 TRIALIM | Jan 6, 2021 | Other filings | ASX |
|---|
| Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial | Dec 16, 2020 | Other filings | ASX |
|---|
| Imugene Receives $4.82 million R&D Tax Incentive | Dec 10, 2020 | Other filings | ASX |
|---|
| Imugene First Patient Dosed in PD1-VAXX Clinical Trial | Nov 30, 2020 | Other filings | ASX |
|---|
| Imugene HER Vaxx shows positive Overall Survival in trial | Nov 22, 2020 | Other filings | ASX |
|---|
| Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA | Nov 1, 2020 | Other filings | ASX |
|---|
| Imugene Immunotherapy Combination Patent Granted in US | Oct 1, 2020 | Other filings | ASX |
|---|
| Imugene Secures $5.7 million Option Underwriting Agreement | Sep 8, 2020 | Other filings | ASX |
|---|
| Imugene Receives PD1-VAXX Ethics Trial Approval in USA | Sep 3, 2020 | Other filings | ASX |
|---|
| Appendix 4E & Annual Report to shareholders | Aug 31, 2020 | Annual report | ASX |
|---|
| Imugene Receives Third PD1-VAXX Ethics Trial Approval | Aug 20, 2020 | Other filings | ASX |
|---|
| Imugene Receives Clinical Guidance from US FDA for Vaxinia | Aug 5, 2020 | Guidance | ASX |
|---|
| Imugene Receives Second PD1-VAXX Ethics Trial Approval | Jul 16, 2020 | Other filings | ASX |
|---|
| Imugene Receives Ethics Approval to Start PD1-VAXX Trial | Jul 13, 2020 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Phase 2 Clinical Update | May 3, 2020 | Other filings | ASX |
|---|
| Imugene PD1-Vaxx Immunotherapy Update | Jan 27, 2020 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Immunotherapy Patent Granted in US | Jan 13, 2020 | Other filings | ASX |
|---|
This page holds 200 of 258 filings. Open Filings
Open Filings
Cap table
Built by 6ix from Imugene Ltd’s releases · as of Sep 1, 2026
- Common shares
- 554,067,948
- Fully diluted
- 554,067,948
Fully diluted
| Line | Shares |
|---|
| Common shares | 554,067,948 |
|---|
Warrants and options
| Lot |
|---|
| Warrants · A$0.0664 · expire about Aug 2031 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 554,067,948 |
|---|
Open Cap table
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
| Charmaine Gittleson | Non-Executive Director · Since at least Nov 12, 2026 |
|---|
| Jakob Dupont | Non-Executive Director · Since at least Nov 12, 2026 |
|---|
| Josep Tabernero | President of ESMO · Nov 4, 2026 – Nov 11, 2026 · Past |
|---|
| Kim Drapkin | Non-Executive Director · Since at least Nov 12, 2026 |
|---|
| Lesley Russell | Non-Executive Director · Nov 11, 2026 – Nov 11, 2026 · Past |
|---|
| Michael Kotsanis | Non-Executive Director · Since at least Nov 12, 2026 |
|---|
| Paul Hopper | Executive Chairman · Since at least Nov 12, 2026 |
|---|
| Prasad S. Adusumilli | Director · Nov 4, 2026 – Nov 11, 2026 · Past |
|---|
| Yuman Fong | Chair of the Department of Surgery · Nov 4, 2026 – Nov 11, 2026 · Past |
|---|
Open People
Log in to ask 6ix AI your own questions about Imugene Ltd.